---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-011402"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2025-07-25T23:59:59+00:00"
generated_at: "2026-05-18T00:55:35.510899+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Daré Bioscience regains Nasdaq compliance but faces one-year Mandatory Panel Monitor

## Summary
- Received Nasdaq letter confirming compliance with stockholders' equity rule (Nasdaq 5550(b)(1)) on July 24, 2025.
- Subject to Mandatory Panel Monitor for one year from July 24, 2025.
- If non-compliance within year, delist determination with no right to submit compliance plan or cure period.

## SEC filing metadata
- accession: 0001493152-25-011402
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2025-07-25T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000149315225011402/0001493152-25-011402-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000149315225011402/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-011402
- JSON: https://secwatch.observer/filing/0001493152-25-011402.json
- Plain text: https://secwatch.observer/filing/0001493152-25-011402.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.